Question 1

What makes Retatrutide a 'Triple Agonist'?

Accepted Answer

Unlike Semaglutide (1 receptor) or Tirzepatide (2 receptors), Retatrutide targets 3 distinct metabolic receptors: GLP-1, GIP, and Glucagon.

Question 2

Why include the Glucagon receptor?

Accepted Answer

While GLP-1 and GIP handle insulin and appetite, the Glucagon receptor directly targets the liver to burn stored fat (hepatic steatosis) and actively increases the subject’s resting metabolic rate.

Question 3

Is Retatrutide approved for human clinical use?

Accepted Answer

No. Retatrutide is currently an experimental compound. Melbourne Peptides supplies it strictly for in-vitro laboratory research and analytical modeling.